Interim report - Q1 2018/19 - Digital build-up drives

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
62
Interim report - Q1 2018/19 - Digital build-up drives growth in sales and footfall in Q1

Company announcement no. 4 2018/19 Allerød, 22 August 2018

Interim report – Q1 2018/19

(1 April – 30 June 2018)

Digital build-up drives growth in sales and footfall in Q1 

“The 2018/19 financial year has started off on a strong note with increased footfall and growing sales. In total, 120,000 more transactions were completed compared to Q1 last year, and growth was driven primarily by the digital initiatives launched in respect of matas.dk at the beginning of the calendar year. In addition, the sunny summer triggered a strong increase in sunscreen sales. The quarter also benefitted from a positive calendar effect. Revenue for the first quarter of the financial year was DKK 843.8 million, a year-on-year increase of 1.6%. Underlying like-for-like revenue growth was 1.1%”, says Gregers Wedell-Wedellsborg, CEO of Matas A/S, and adds:

“Due to one-off severance costs in connection with a management reshuffle, the Q1 profit after tax was slightly down on Q1 2017/18, while the EBITDA margin adjusted for exceptional items was in line with the first quarter of 2017/18.

At the beginning of the year, we launched the Matas 4D digital growth plan, setting out, among other things, to make shopping on matas.dk faster and easier. As part of this plan, we have introduced nationwide next day delivery, while in Greater Copenhagen we offer same day delivery for orders placed by 3 p.m. Our customers have really responded well to this initiative, and online sales grew by 50% in the past quarter.

Customers have also embraced our measures to add competitive power, including ‘Fair prices’ on a selection of everyday products. Mass Beauty sales grew by 0.4% in the past quarter, supported by the relaunch of the Sun Stripes range and the introduction of a green sunblock series within the Matas Natur range.”

Q1 2018/19 highlights

  • Management presented the Group’s updated strategy going forward to 2023, “A renewed Matas”, at its capital markets day on 30 May 2018, which was held in connection with the presentation of the Group’s financial statements for financial year 2017/18. The work to implement the strategy is progressing according to plan, and a range of measures was launched in the first quarter to enhance customer satisfaction, grow revenue and sustain earnings.
  • Q1 2018/19 revenue came to DKK 843.8 million, up 1.6% on the DKK 830.8 million reported for Q1 2017/18 (restated, see note 1). Underlying like-for-like sales, i.e. sales in stores operated by the Group in both Q1 2018/19 and Q1 2017/18, were up by 1.1% in Q1 2018/19. The positive calendar effect contributed with around 0.5% of the underlying growth in sales.
  • Revenue was supported by increased sales in all shops-in-shop except the MediCare shop, which reported unchanged sales. The High-End Beauty and Vital segments reported the strongest sales growth. The average basket size grew by 1.6% to DKK 157.6, and the number of transactions was up by 2.3% from 5.2 million in Q1 2017/18 to 5.3 million in Q1 2018/19.
  • Online sales were up by 50% year-on-year. More than half of all orders were picked up at a Matas store.
  • The Vital and High-End Beauty segments performed satisfactorily, reporting sales growth of 7.4% and 4.5%, respectively. Supported by higher sunblock sales, Mass Beauty revenue was slightly up on the year-earlier period.
  • Q1 2018/19 gross profit was DKK 381.7 million, taking the gross margin to 45.2%, a slight 0.4 percentage point decline from 45.6% in Q1 2017/18.
  • Total costs increased by DKK 5.8 million relative to the year-earlier period. Adjusted for non-recurring costs incurred in connection with a management reshuffle etc., costs were up by DKK 0.8 million.
  • Q1 2018/19 EBITDA came to DKK 133.3 million for an EBITDA margin of 15.8%, as compared with 16.4% for Q1 2017/18. The EBITA margin was driven down by exceptional items in the form of the above-mentioned non-recurring costs in connection with the management reshuffle.
  • Q1 2018/19 EBITDA before exceptional items came to DKK 138.3 million for an EBITDA margin of 16.4%, unchanged relative to Q1 2017/18.
  • Q1 profit after tax was DKK 70.8 million, and Adjusted profit after tax net of amortisation not related to software and exceptional items was DKK 89.7 million, compared with DKK 74.0 million and DKK 88.9 million, respectively, in Q1 2017/18.
  • Cash generated from operations grew to DKK 105.3 million in Q1 2018/19 from DKK 76.7 million in the year-earlier period. The free cash flow was an inflow of DKK 72.9 million against an inflow of DKK 33.3 million in Q1 2017/18.
  • Gross debt stood at DKK 1,593.7 million at 30 June 2018. Net interest-bearing debt was DKK 1,399.4 million at 30 June 2018, equivalent to 2.5x LTM EBITDA before exceptional items and unchanged relative to the end of Q1 2017/18.

Outlook

We reiterate our guidance for financial year 2018/19:

  • Underlying revenue unchanged relative to 2017/18 (like-for-like growth in the -1% – 1% range).
  • An EBITDA margin above 14.5%.
  • CAPEX between DKK 110 million and DKK 130 million.

Our financial guidance for 2018/19 is based on assumptions of slightly growing consumer spending, a continuing decline in physical store footfall and persistently intensive competition in the health, beauty and personal care market.

Our guidance includes costs for implementing Matas’s growth strategy.

The 2018/19 financial year contains an extra trading day compared to FY 2017/18, which is expected to have a slightly positive effect on revenue.

 

Conference call

Matas will host a conference call for investors and analysts on Wednesday, 22 August 2018 at 10:00 a.m. The conference call and presentation can be accessed on our investor website: www.investor.en.matas.dk.

Conference call access numbers for investors and analysts: DK                                                     +45 35 15 81 21 UK:                                                    +44 (0)330 336 9411 US:                                                    +1 929-477-0402 Event code:                                     3298039

Link to webcast:                             https://edge.media-server.com/m6/p/w5q3r742

Contacts

Gregers Wedell-Wedellsborg                                                             Anders T. Skole-Sørensen                                            CEO, tel +45 48 16 55 55                                                                     CFO, tel +45 48 16 55 55               

Elisabeth Toftmann Klintholm                                                                Head of Investor Relations & Corp. Affairs, tel +45 48 16 55 48     

Forward-looking statements

This interim report contains statements relating to the future, including statements regarding the Matas Group's future operating results, financial position, cash flows, business strategy and future targets. Such statements are based on management’s reasonable expectations and forecasts at the time of release of the interim report. Forward-looking statements are subject to risks and uncertainties and a number of other factors, many of which are beyond the Matas Group's control. This may have the effect that actual results may differ significantly from the expectations expressed in the interim report. Without being exhaustive, such factors include general economic and commercial factors, including market and competitive conditions, supplier issues and financial and regulatory issues.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading

Top 5 Most Recently Viewed Articles

Veriforce Expands Its Mission with Highwire Acquisition

Updated Category News Views 471

Veriforce Expands Its Mission with Highwire Acquisition The combined expertise delivers stronger safety, compliance, and financial risk management for construction projects worldwide Veriforce, a leader in contractor management and supply chain risk management, has recently announced its acquisition of Highwire. This acquisition is significant in the realm of contractor...

Continue Reading
Tyra Biosciences Achieves Key Preclinical Results, Analysts Upgrades

Updated Category News Views 104

Tyra Biosciences Receives Analyst Upgrade BofA Securities has recently upgraded Tyra Biosciences (NASDAQ: TYRA), a clinical-stage biotechnology firm specializing in the creation of next-generation precision medicines. This upgrade highlights investor optimism as the company demonstrates promising results in its drug development process. Focus on Precision Medicine in...

Continue Reading
ConnX Partners with SEPTA for Enhanced Cloud Communication

Updated Category News Views 254

ConnX landed a hefty contract back in 2024 with the Southeastern Pennsylvania Transportation Authority (SEPTA) for a major overhaul of their communications network. The deal’s supposed to create a seamless communication experience, but you know how these things go—desks are skeptical about the actual impact. SEPTA's Communication Crisis: Is Cloud the Answer? SEPTA,...

Continue Reading
Kinepolis Group Announces Upcoming Dividend Payment Details

Updated Category News Views 197

Kinepolis Group Dividend Announcement The Kinepolis Group NV is pleased to inform its shareholders of an upcoming dividend payout, a noteworthy event for investors looking to maximize their returns. Dividend Payment Details The company has officially announced a gross dividend of €0.55 per share. After the deduction of the standard 30% withholding tax, shareholders will...

Continue Reading
Cargotec Board Restructures Ahead of Exciting Name Change

Updated Category News Views 229

Cargotec's Board of Directors Restructuring Meeting Highlights Cargotec Corporation has made significant decisions during its recent Board of Directors meeting, as it prepares for exciting changes ahead. Notably, the Board has elected Jukka Moisio as Chair, continuing a strong leadership footprint. Alongside him, Casimir Lindholm has been appointed Vice Chair, effective...

Continue Reading